BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 16977397)

  • 1. [Zygomycosis after hematogeneic stem cell transplantation--a current problem?].
    Glöckner A; Cornely OA
    Med Klin (Munich); 2006 Sep; 101(9):724-9. PubMed ID: 16977397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zygomycosis--current epidemiological aspects.
    Glöckner A; Vehreschild JJ; Cornely OA
    Mycoses; 2007; 50 Suppl 1():50-5. PubMed ID: 17394610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy.
    Trifilio SM; Bennett CL; Yarnold PR; McKoy JM; Parada J; Mehta J; Chamilos G; Palella F; Kennedy L; Mullane K; Tallman MS; Evens A; Scheetz MH; Blum W; Kontoyiannis DP
    Bone Marrow Transplant; 2007 Apr; 39(7):425-9. PubMed ID: 17310132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis.
    Siwek GT; Dodgson KJ; de Magalhaes-Silverman M; Bartelt LA; Kilborn SB; Hoth PL; Diekema DJ; Pfaller MA
    Clin Infect Dis; 2004 Aug; 39(4):584-7. PubMed ID: 15356827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole.
    Trifilio S; Singhal S; Williams S; Frankfurt O; Gordon L; Evens A; Winter J; Tallman M; Pi J; Mehta J
    Bone Marrow Transplant; 2007 Sep; 40(5):451-6. PubMed ID: 17589527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of invasive aspergillosis among allogeneic hematopoietic stem cell transplant patients receiving voriconazole prophylaxis.
    Siwek GT; Pfaller MA; Polgreen PM; Cobb S; Hoth P; Magalheas-Silverman M; Diekema DJ
    Diagn Microbiol Infect Dis; 2006 Jul; 55(3):209-12. PubMed ID: 16626917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk stratification and targeted antifungal prophylaxis for prevention of aspergillosis and other invasive mold infections after liver transplantation.
    Hellinger WC; Bonatti H; Yao JD; Alvarez S; Brumble LM; Keating MR; Mendez JC; Kramer DJ; Dickson RC; Harnois DM; Spivey JR; Hughes CB; Nguyen JH; Steers JL
    Liver Transpl; 2005 Jun; 11(6):656-62. PubMed ID: 15915482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry.
    Neofytos D; Horn D; Anaissie E; Steinbach W; Olyaei A; Fishman J; Pfaller M; Chang C; Webster K; Marr K
    Clin Infect Dis; 2009 Feb; 48(3):265-73. PubMed ID: 19115967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of zygomycosis in transplant recipients.
    Cuenca-Estrella M; Bernal-Martinez L; Isla G; Gomez-Lopez A; Alcazar-Fuoli L; Buitrago MJ
    Clin Microbiol Infect; 2009 Oct; 15 Suppl 5():37-40. PubMed ID: 19754755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Higher risk of cytomegalovirus and aspergillus infections in recipients of T cell-depleted unrelated bone marrow: analysis of infectious complications in patients treated with T cell depletion versus immunosuppressive therapy to prevent graft-versus-host disease.
    van Burik JA; Carter SL; Freifeld AG; High KP; Godder KT; Papanicolaou GA; Mendizabal AM; Wagner JE; Yanovich S; Kernan NA
    Biol Blood Marrow Transplant; 2007 Dec; 13(12):1487-98. PubMed ID: 18022579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases.
    Kontoyiannis DP; Lionakis MS; Lewis RE; Chamilos G; Healy M; Perego C; Safdar A; Kantarjian H; Champlin R; Walsh TJ; Raad II
    J Infect Dis; 2005 Apr; 191(8):1350-60. PubMed ID: 15776383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nosocomial fungal infections. Old problems and new challenges.
    Anaissie E; Bodey GP
    Infect Dis Clin North Am; 1989 Dec; 3(4):867-82. PubMed ID: 2687366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breakthrough Scedosporium prolificans infection while receiving voriconazole prophylaxis in an allogeneic stem cell transplant recipient.
    Tong SY; Peleg AY; Yoong J; Handke R; Szer J; Slavin M
    Transpl Infect Dis; 2007 Sep; 9(3):241-3. PubMed ID: 17605752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rethinking the use of voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients.
    Brown J; Freeman BB
    Bone Marrow Transplant; 2005 Jul; 36(2):177. PubMed ID: 15908975
    [No Abstract]   [Full Text] [Related]  

  • 16. Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMT.
    Ljungman P; Engelhard D; de la Cámara R; Einsele H; Locasciulli A; Martino R; Ribaud P; Ward K; Cordonnier C;
    Bone Marrow Transplant; 2005 Apr; 35(8):737-46. PubMed ID: 15750612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of infectious complications in the hematopoietic stem cell transplant recipient.
    Nichols WG
    J Intensive Care Med; 2003; 18(6):295-312. PubMed ID: 14984659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors for invasive fungal infections in haematopoietic stem cell transplantation.
    Camps IR
    Int J Antimicrob Agents; 2008 Nov; 32 Suppl 2():S119-23. PubMed ID: 19013335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for late infections after allogeneic hematopoietic stem cell transplantation from a matched related donor.
    Robin M; Porcher R; De Castro Araujo R; de Latour RP; Devergie A; Rocha V; Larghero J; Adès L; Ribaud P; Mary JY; Socié G
    Biol Blood Marrow Transplant; 2007 Nov; 13(11):1304-12. PubMed ID: 17950917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changing landscape of invasive aspergillosis in allogeneic stem cell transplant recipients.
    Jantunen E; Nihtinen A; Anttila VJ
    Transpl Infect Dis; 2008 Jun; 10(3):156-61. PubMed ID: 18266785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.